iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is headed up in the market this morning. However, the company’s most recent news was issued 6 days ago. So, that’s clearly not the catalyst here. So, what’s the deal?

Well, it all seems to have to do with an SEC filing that suggests that an institutional player has taken a substantial interest in the company. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Pops On Institutional Ownership

The institutional ownership update came late yesterday by way of SEC filing. According to the filing, Eastern Capital Limited disclosed that it now owns 37,382,734 shares of IBIO stock. As such, Eastern Capital now owns about 28.7% of the company’s outstanding common stock.

So, what’s the big deal?

Well, in the market smart money tends to follow big money. After all, institutional investors have employees whose job is to do nothing but analyze the market. These guys live, eat and breath market analysis.

So, when a big money player jumps in head first like this, it suggests that strong growth is on the horizon. So, it’s not surprising to see that with the SEC filing in mind, investors are showing increased interest in IBIO.

Why Is Eastern Capital So Interested?

SEC filings don’t require investors to share their thoughts as to why they are interested, but there’s good reason to be interested in iBio.

We all know that the coronavirus pandemic is a serious issue. Unfortunately, the pandemic is changing life as we know it through school and event closures, empty retail shelves and streets, and more. All in all, the medical community desperately needs a vaccine here.

That’s where IBIO comes in. The company was one of the first that announced that it was working on a vaccine candidate for COVID-19. In the announcement, the company said that it partnered with CC Pharming, a Chinese company who has already created a vaccine for a cousin strain of the coronavirus.

Moreover, IBIO has the FastPharming Facility, which offers up a major advantage. The facility was commissioned by the United States Department of Defense. The goal was to have a facility that could create and manufacture vaccines at a rapid rate in times of a pandemic.

So, iBio’s FastPharming Facility was built for times just like these! With a strong partner, the FastPharming Facility, and continued work to bring a coronavirus vaccine to market, IBIO stock is one of great interest not only in the institutional sense, but also among retail investors.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.